Drug Approval | January 28, 2024
Shilpa Medicare updates on Europe GMP inspection at Unit 4, Jadcherla, Telangana
The company intends to respond to the two minor observations within the stipulated time
The company intends to respond to the two minor observations within the stipulated time
Dr. Mandaviya also laid the foundation stone for an All India Institute of Speech and Hearing (AIISH) Satellite Centre in Kanpur
Tornado will enhance Bruker’s biopharma PAT portfolio with its well-established products
Elpiscience will receive up to US $37 million, including the upfront payment and license option fees
Loteprednol Etabonate Ophthalmic Suspension, 0.2%, is indicated for the temporary relief of the signs and symptoms of seasonal allergic conjunctivitis
The product is expected to be launched in December 2023
Atlas Life Sciences (India) has successfully commenced the commercial production of API - Intermediate at its new plant at Chhatral,
The current annual U.S. market for Sildenafil for Oral Suspension is approximately $43 million
The company has received Form 483 with three observations
The product is expected to be launched in FY25
Subscribe To Our Newsletter & Stay Updated
